{"component": "clause", "props": {"groups": [{"samples": [{"hash": "6Yj3GD7cbWG", "uri": "/contracts/6Yj3GD7cbWG#research-activities", "label": "Consortium Agreement", "score": 28.059671402, "published": true}, {"hash": "fFOLOaHKwQJ", "uri": "/contracts/fFOLOaHKwQJ#research-activities", "label": "Consortium Agreement", "score": 27.1426525116, "published": true}, {"hash": "vYYv8jhuqT", "uri": "/contracts/vYYv8jhuqT#research-activities", "label": "Consortium Agreement", "score": 26.0624084473, "published": true}], "snippet_links": [{"key": "development-activities", "type": "definition", "offset": [71, 93]}, {"key": "specific-outcomes", "type": "clause", "offset": [98, 115]}, {"key": "the-activities", "type": "clause", "offset": [119, 133]}, {"key": "the-project", "type": "definition", "offset": [137, 148]}, {"key": "be-guaranteed", "type": "clause", "offset": [156, 169]}, {"key": "the-parties-acknowledge", "type": "clause", "offset": [171, 194]}, {"key": "party-to-this-agreement", "type": "clause", "offset": [278, 301]}, {"key": "pertaining-to", "type": "definition", "offset": [303, 316]}, {"key": "anticipated-outcome", "type": "clause", "offset": [321, 340]}], "snippet": "Uncertainties of effects and results are typical to all re- search and development activities and specific outcomes of the activities in the Project cannot be guaranteed. The Parties acknowledge and accept these uncertainties and agree not to bring any claims against any other Party to this Agreement, pertaining to the anticipated outcome or the results and success of the Project.", "size": 6, "hash": "a54acac1e022d8f5c5d344475438c867", "id": 1}, {"samples": [{"hash": "8sjCjK9Pm0m", "uri": "/contracts/8sjCjK9Pm0m#research-activities", "label": "Collaboration and License Agreement (Exscientia PLC)", "score": 34.22108078, "published": true}, {"hash": "6az2w70bfBX", "uri": "/contracts/6az2w70bfBX#research-activities", "label": "Collaboration and License Agreement (Exscientia PLC)", "score": 33.2217674255, "published": true}], "snippet_links": [{"key": "designation-of-a", "type": "clause", "offset": [18, 34]}, {"key": "the-parties-shall", "type": "clause", "offset": [93, 110]}, {"key": "small-molecule", "type": "definition", "offset": [124, 138]}, {"key": "in-accordance-with", "type": "definition", "offset": [195, 213]}, {"key": "research-plan", "type": "definition", "offset": [244, 257]}, {"key": "provided-that", "type": "definition", "offset": [299, 312]}, {"key": "research-projects", "type": "clause", "offset": [373, 390]}, {"key": "for-clarity", "type": "clause", "offset": [392, 403]}, {"key": "during-the-research-term", "type": "clause", "offset": [486, 510]}, {"key": "number-of", "type": "clause", "offset": [532, 541]}, {"key": "development-candidates", "type": "clause", "offset": [641, 663]}, {"key": "for-the-avoidance-of-doubt", "type": "clause", "offset": [745, 771]}, {"key": "collaboration-targets", "type": "definition", "offset": [857, 878]}, {"key": "neither-party-shall", "type": "clause", "offset": [880, 899]}, {"key": "use-commercially-reasonable-efforts", "type": "clause", "offset": [992, 1027]}, {"key": "allocated-to", "type": "definition", "offset": [1058, 1070]}, {"key": "comply-with-applicable-laws", "type": "clause", "offset": [1214, 1241]}, {"key": "in-the-performance", "type": "clause", "offset": [1373, 1391]}, {"key": "relevant-qualifications", "type": "clause", "offset": [1540, 1563]}, {"key": "training-and-experience", "type": "clause", "offset": [1565, 1588]}, {"key": "from-time-to-time", "type": "clause", "offset": [1758, 1775]}, {"key": "the-joint-steering-committee", "type": "clause", "offset": [1779, 1807]}, {"key": "clause-11", "type": "clause", "offset": [1827, 1836]}, {"key": "subcontracting-party", "type": "definition", "offset": [1859, 1879]}, {"key": "an-affiliate", "type": "clause", "offset": [1893, 1905]}, {"key": "its-responsibilities", "type": "clause", "offset": [1953, 1973]}, {"key": "prior-to", "type": "clause", "offset": [2016, 2024]}, {"key": "third-party-subcontractors", "type": "clause", "offset": [2066, 2092]}, {"key": "consent-of", "type": "clause", "offset": [2131, 2141]}, {"key": "agreed-that", "type": "clause", "offset": [2157, 2168]}, {"key": "the-subcontractors", "type": "clause", "offset": [2169, 2187]}, {"key": "schedule-2", "type": "definition", "offset": [2198, 2208]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [2224, 2248]}, {"key": "affiliate-or-subcontractor", "type": "clause", "offset": [2260, 2286]}, {"key": "qualifications-and-standards", "type": "clause", "offset": [2297, 2325]}, {"key": "required-by", "type": "definition", "offset": [2336, 2347]}, {"key": "performance-of-work", "type": "clause", "offset": [2381, 2400]}, {"key": "scope-and", "type": "clause", "offset": [2412, 2421]}, {"key": "subcontracted-activity", "type": "definition", "offset": [2440, 2462]}, {"key": "control-of", "type": "definition", "offset": [2528, 2538]}, {"key": "patent-rights", "type": "definition", "offset": [2543, 2556]}, {"key": "created-by", "type": "definition", "offset": [2605, 2615]}, {"key": "in-connection-with", "type": "clause", "offset": [2657, 2675]}, {"key": "responsible-for", "type": "clause", "offset": [2734, 2749]}, {"key": "acts-and-omissions", "type": "clause", "offset": [2754, 2772]}, {"key": "with-respect-to", "type": "clause", "offset": [2893, 2908]}, {"key": "days-after", "type": "definition", "offset": [3016, 3026]}, {"key": "calendar-quarter", "type": "definition", "offset": [3043, 3059]}, {"key": "will-provide", "type": "clause", "offset": [3068, 3080]}, {"key": "an-invoice", "type": "clause", "offset": [3088, 3098]}, {"key": "expenses-incurred", "type": "definition", "offset": [3112, 3129]}, {"key": "by-sanofi", "type": "clause", "offset": [3138, 3147]}, {"key": "in-clause", "type": "clause", "offset": [3303, 3312]}, {"key": "costs-and-expenses", "type": "clause", "offset": [3361, 3379]}, {"key": "by-or-on-behalf-of", "type": "definition", "offset": [3389, 3407]}, {"key": "in-relation-to", "type": "clause", "offset": [3414, 3428]}, {"key": "subject-of", "type": "clause", "offset": [3536, 3546]}, {"key": "provide-a", "type": "definition", "offset": [3587, 3596]}, {"key": "report-to", "type": "definition", "offset": [3605, 3614]}, {"key": "data-and-information", "type": "definition", "offset": [3750, 3770]}, {"key": "necessary-for", "type": "definition", "offset": [3809, 3822]}, {"key": "to-determine", "type": "definition", "offset": [3830, 3842]}, {"key": "lead-identification", "type": "clause", "offset": [3928, 3947]}, {"key": "determine-whether", "type": "clause", "offset": [4136, 4153]}, {"key": "the-applicable", "type": "clause", "offset": [4161, 4175]}, {"key": "notice-of", "type": "definition", "offset": [4237, 4246]}, {"key": "such-determination", "type": "definition", "offset": [4247, 4265]}, {"key": "the-research-program", "type": "clause", "offset": [4356, 4376]}, {"key": "to-the-extent", "type": "clause", "offset": [4444, 4457]}, {"key": "research-milestone-payment", "type": "definition", "offset": [4554, 4580]}, {"key": "terms-of-this-agreement", "type": "clause", "offset": [4678, 4701]}, {"key": "conclusion-of", "type": "clause", "offset": [4879, 4892]}, {"key": "development-candidate-data-package", "type": "definition", "offset": [5085, 5119]}, {"key": "additional-information", "type": "clause", "offset": [5134, 5156]}, {"key": "reasonably-request", "type": "definition", "offset": [5173, 5191]}, {"key": "research-tools", "type": "definition", "offset": [5243, 5257]}, {"key": "lead-molecule", "type": "definition", "offset": [5591, 5604]}, {"key": "the-development", "type": "clause", "offset": [5844, 5859]}, {"key": "notwithstanding-anything-to-the-contrary", "type": "clause", "offset": [6246, 6286]}, {"key": "without-limiting", "type": "clause", "offset": [6306, 6322]}, {"key": "data-packages", "type": "clause", "offset": [6374, 6387]}, {"key": "as-required", "type": "clause", "offset": [6426, 6437]}, {"key": "notice-to", "type": "clause", "offset": [6473, 6482]}, {"key": "date-of-delivery", "type": "definition", "offset": [6685, 6701]}, {"key": "acting-reasonably", "type": "clause", "offset": [6899, 6916]}, {"key": "in-good-faith", "type": "definition", "offset": [6921, 6934]}, {"key": "amendments-to", "type": "clause", "offset": [6956, 6969]}, {"key": "date-for-delivery", "type": "definition", "offset": [7121, 7138]}, {"key": "to-amend", "type": "definition", "offset": [7207, 7215]}, {"key": "for-purposes-of", "type": "clause", "offset": [7564, 7579]}, {"key": "agreement-to", "type": "clause", "offset": [7721, 7733]}, {"key": "amendment-to", "type": "definition", "offset": [7747, 7759]}, {"key": "purpose-of", "type": "clause", "offset": [7779, 7789]}, {"key": "receipt-of-a", "type": "clause", "offset": [7878, 7890]}, {"key": "in-writing", "type": "clause", "offset": [8026, 8036]}, {"key": "deliver-to", "type": "definition", "offset": [8242, 8252]}, {"key": "the-relevant", "type": "clause", "offset": [8468, 8480]}, {"key": "information-regarding", "type": "clause", "offset": [8495, 8516]}, {"key": "relating-to", "type": "definition", "offset": [8575, 8586]}, {"key": "to-discuss", "type": "definition", "offset": [8696, 8706]}, {"key": "complete-and-accurate", "type": "clause", "offset": [8785, 8806]}, {"key": "written-records", "type": "clause", "offset": [8807, 8822]}, {"key": "results-and-data", "type": "clause", "offset": [8862, 8878]}, {"key": "pursuant-to", "type": "definition", "offset": [8888, 8899]}, {"key": "sufficient-detail", "type": "clause", "offset": [8944, 8961]}, {"key": "in-addition-to-the", "type": "clause", "offset": [9040, 9058]}, {"key": "reporting-obligations", "type": "definition", "offset": [9059, 9080]}, {"key": "reasonable-request", "type": "definition", "offset": [9112, 9130]}, {"key": "reasonable-access", "type": "definition", "offset": [9183, 9200]}, {"key": "data-and-data", "type": "clause", "offset": [9248, 9261]}, {"key": "contained-in", "type": "definition", "offset": [9262, 9274]}, {"key": "laboratory-notebooks", "type": "clause", "offset": [9275, 9295]}, {"key": "course-of-performance", "type": "clause", "offset": [9322, 9343]}, {"key": "both-parties", "type": "definition", "offset": [9425, 9437]}, {"key": "interim-results", "type": "definition", "offset": [9449, 9464]}, {"key": "arising-out-of", "type": "definition", "offset": [9513, 9527]}, {"key": "review-of", "type": "clause", "offset": [9650, 9659]}, {"key": "alliance-manager", "type": "definition", "offset": [9725, 9741]}, {"key": "adjustments-to", "type": "clause", "offset": [9762, 9776]}, {"key": "to-account", "type": "definition", "offset": [9836, 9846]}, {"key": "the-right", "type": "clause", "offset": [9919, 9928]}, {"key": "upon-reasonable-notice", "type": "clause", "offset": [9958, 9980]}, {"key": "copies-of", "type": "definition", "offset": [9997, 10006]}, {"key": "confidential-information-of-each-party", "type": "clause", "offset": [10129, 10167]}, {"key": "without-affecting", "type": "clause", "offset": [10169, 10186]}, {"key": "ownership-of", "type": "clause", "offset": [10191, 10203]}, {"key": "confidentiality-and-non", "type": "clause", "offset": [10207, 10230]}, {"key": "use-obligations", "type": "clause", "offset": [10231, 10246]}, {"key": "related-to", "type": "clause", "offset": [10247, 10257]}, {"key": "the-information", "type": "clause", "offset": [10258, 10273]}, {"key": "each-party-will", "type": "clause", "offset": [10289, 10304]}, {"key": "furnish-to", "type": "clause", "offset": [10305, 10315]}, {"key": "committee-meeting", "type": "definition", "offset": [10369, 10386]}, {"key": "applicable-to", "type": "clause", "offset": [10402, 10415]}, {"key": "such-party", "type": "clause", "offset": [10416, 10426]}, {"key": "provide-the", "type": "clause", "offset": [10813, 10824]}, {"key": "other-results", "type": "clause", "offset": [10860, 10873]}, {"key": "data-and-other-information", "type": "clause", "offset": [10875, 10901]}, {"key": "activities-under", "type": "clause", "offset": [10922, 10938]}, {"key": "member-of-the", "type": "clause", "offset": [10985, 10998]}, {"key": "possession-or-control", "type": "definition", "offset": [11072, 11093]}, {"key": "under-clause", "type": "clause", "offset": [11198, 11210]}, {"key": "to-exercise", "type": "clause", "offset": [11234, 11245]}, {"key": "rights-under-this-agreement", "type": "clause", "offset": [11250, 11277]}, {"key": "by-a-party", "type": "clause", "offset": [11303, 11313]}, {"key": "other-party", "type": "clause", "offset": [11357, 11368]}, {"key": "access-to-records", "type": "clause", "offset": [11460, 11477]}, {"key": "request-for", "type": "definition", "offset": [11683, 11694]}, {"key": "nothing-in-this-clause", "type": "clause", "offset": [12016, 12038]}, {"key": "to-provide", "type": "clause", "offset": [12065, 12075]}, {"key": "contrary-to", "type": "definition", "offset": [12125, 12136]}, {"key": "right-to-perform", "type": "clause", "offset": [12180, 12196]}, {"key": "in-the-event-of-a-dispute", "type": "clause", "offset": [12293, 12318]}, {"key": "performed-by", "type": "clause", "offset": [12363, 12375]}, {"key": "final-decision", "type": "definition", "offset": [12426, 12440]}, {"key": "approval-of", "type": "clause", "offset": [12544, 12555]}, {"key": "at-no-cost", "type": "definition", "offset": [12659, 12669]}, {"key": "terms-and-conditions-of-this-agreement", "type": "clause", "offset": [12756, 12794]}, {"key": "material-transfer-agreement", "type": "definition", "offset": [12844, 12871]}, {"key": "entered-into", "type": "clause", "offset": [12872, 12884]}, {"key": "between-the-parties", "type": "clause", "offset": [12885, 12904]}, {"key": "schedule-5", "type": "definition", "offset": [13046, 13056]}, {"key": "directed-to", "type": "definition", "offset": [13123, 13134]}, {"key": "other-materials", "type": "clause", "offset": [13171, 13186]}, {"key": "each-case", "type": "definition", "offset": [13191, 13200]}, {"key": "provided-data", "type": "clause", "offset": [13315, 13328]}], "snippet": "5.1 Following the designation of a Collaboration Target as an Approved Collaboration Target, the Parties shall commence the Small Molecule Research Project for that Approved Collaboration Target in accordance with this Agreement (including the Research Plan for that Approved Collaboration Target), provided that: (a) there will be no more than [***] active Small Molecule Research Projects (for clarity, excluding any Research Program for a Collaboration NSM Target) at any given time during the Research Term; and (b) the maximum number of active Small Molecule Research Projects in sub-clause (a) will [***] each time [***] Collaboration Development Candidates are selected for an Approved Collaboration Target in accordance with Clause 6.1. For the avoidance of doubt, if one or more Collaboration Development Candidates are selected for [***] Approved Collaboration Targets, neither Party shall be required to carry out any further Small Molecule Research Projects.\n5.2 Each Party shall use Commercially Reasonable Efforts to undertake those activities allocated to it in each Research Plan and NSM Research Plan in accordance with such Research Plan or NSM Research Plan and this Agreement. Each Party shall comply with Applicable Laws in performing those activities allocated to it in the Research Plan.\n5.3 Each Party shall ensure that all of its personnel engaged in the performance of any of that Party\u2019s responsibilities under each Research Plan or NSM Research Plan (a) are competent and efficient; and (b) have appropriate and relevant qualifications, training and experience for, and are knowledgeable about, that Party\u2019s responsibilities under that Research Plan or NSM Research Plan.\n5.4 Any Research Plan or NSM Research Plan may be amended from time to time by the Joint Steering Committee in accordance with Clause 11.\n5.5 Each Party (the \u201cSubcontracting Party\u201d) may engage an Affiliate or Third Party subcontractor to perform any of its responsibilities under a Research Plan; provided that:\n(a) prior to [***] subcontracting such performance to Third Party subcontractors, [***] shall obtain the prior written consent of [***] it being agreed that the subcontractors listed on Schedule 2 are pre-agreed as of the Effective Date);\n(b) that Affiliate or subcontractor meets the qualifications and standards generally required by the Subcontracting Party for the performance of work similar in scope and complexity to the subcontracted activity;\n(c) the Subcontracting Party ensures that it retains or obtains Control of any Patent Rights, Know-How or other intellectual property rights created by such Affiliate or subcontractor under or in connection with this Agreement; and\n(d) the Subcontracting Party shall be responsible for all acts and omissions of any such Affiliate or subcontractor as fully as if they were the acts and omissions of the Subcontracting Party.\n5.6 With respect to each Research Plan and NSM Research Plan:\n(a) EXS will be responsible for [***] and, within [***] Business Days after the end of each Calendar Quarter, Sanofi will provide to EXS an invoice for any such expenses incurred or paid by Sanofi or its Affiliates during the previous Calendar Quarter. EXS shall pay such invoice within [***] days following receipt thereof; and\n(b) except as provided in Clause 5.6(a) above, [***] will be responsible for all costs and expenses incurred by or on behalf of [***] in relation to the Research Plan or NSM Research Plan.\n5.7 With respect to each Approved Collaboration Target that is the subject of a Research Plan, EXS shall (a) promptly provide a written report to Sanofi when EXS believes that any Small Molecule for an Approved Collaboration Target has achieved [***] and (b) provide to Sanofi all data and information in support thereof that is reasonably necessary for Sanofi to determine that such Small Molecule for such Approved Collaboration Target has achieved [***] (\u201cLead Identification Data Package\u201d). Sanofi shall promptly (and in any event within [***] days after the date of the complete Lead Identification Data Package) evaluate the Lead Identification Data Package to determine whether or not the applicable Small Molecule has achieved [***] and provide prompt written notice of such determination to EXS and, if [***] has been achieved, whether Sanofi wishes to either (i) continue with the Research Program with respect to that Approved Collaboration Target, in which case, to the extent a Research Milestone is payable in accordance with Clause 14.1, Sanofi shall pay the applicable Research Milestone Payment in accordance with this Agreement; or (ii) terminate the Research Program in accordance with the terms of this Agreement.\n5.8 With respect to each Approved Collaboration Target that is the subject of a Research Plan, EXS shall (a) promptly provide (and in any event within [***] days following the conclusion of the Research Plan) a written report to Sanofi when EXS believes that a Small Molecule for such Approved Collaboration Target has achieved [***] and (b) provide to Sanofi (i) the corresponding Development Candidate Data Package and (ii) such additional information that Sanofi may reasonably request and reasonable quantities of any assays, reagents, research tools and such Small Molecules for such Approved Collaboration Target that are reasonably necessary for Sanofi to determine whether such Small Molecule for such Approved Collaboration Target have achieved [***]. Except as otherwise set forth in a corresponding Research Plan, EXS shall deliver a Development Candidate Data Package for the Lead Molecule for an Approved Collaboration Target first and shall deliver a Development Candidate Data Package with respect to [***] Back-Up Molecules [***] for such Approved Collaboration Target by no later than [***] months following the delivery of the Development Candidate Data Package for the Lead Molecule. Sanofi shall promptly (and, in any event, within [***] days after the date of EXS\u2019s delivery of each complete Development Candidate Data Package) evaluate such Development Candidate Data Package to determine whether or not the applicable Small Molecule has achieved [***] and provide prompt written notice of such determination to EXS.\n5.9 Notwithstanding anything to the contrary in Clause 5.8 (but without limiting EXS\u2019s obligations to deliver Development Candidate Data Packages with respect to any Back-Up Molecules as required in Clause 5.8), if Sanofi provides notice to EXS that, with respect to a given Small Molecule for an Approved Collaboration Target, Sanofi desires to obtain delivery of the corresponding Development Candidate Data Package prior to its anticipated date of delivery because Sanofi believes that [***] with respect to that Small Molecule are likely to be met and desires to progress such Small Molecule into Development at an earlier date, then the Parties shall, acting reasonably and in good faith, discuss appropriate amendments to [***]; provided that the Parties intend to not discuss or make any such amendments during the [***] month period immediately preceding the anticipated date for delivery of such Development Candidate Data Package. If the Parties so agree to amend [***] and the applicable Small Molecule achieves the amended [***], then (a) EXS shall promptly deliver the corresponding Development Candidate Data Package to Sanofi within [***] days following the date that [***] amended and (b) such Small Molecule will be deemed to have been designated as a Collaboration Development Candidate that meets [***] for purposes of Clauses 6.1 and [***] as of the date of EXS\u2019s delivery of the corresponding Development Candidate Data Package. [***] shall not withhold its agreement to any proposed amendment to [***] for the sole purpose of delaying the timing [***].\n5.10 By no later than [***] Business Days following Sanofi\u2019s receipt of a Lead Identification Data Package or Development Candidate Data Package for an Approved Collaboration Target, Sanofi may (a) notify EXS in writing that such Lead Identification Data Package or Development Candidate Data Package is incomplete or inconsistent, in which case EXS shall use Commercially Reasonable Efforts to address Sanofi\u2019s concerns and deliver to Sanofi a complete Lead Identification Data Package or Development Candidate Data Package as promptly as practicable or (b) provide EXS with written notice requesting a discussion with EXS representative(s) who have the relevant knowledge and information regarding such Approved Collaboration Target or the Small Molecules relating to such Approved Collaboration Target, in which case EXS shall require such representatives to meet with Sanofi to discuss as soon as reasonably practicable.\n5.11 Each Party shall prepare and maintain complete and accurate written records of all activities performed as well as results and data obtained pursuant to each Research Plan or NSM Research Plan, in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes. In addition to the reporting obligations set forth in Clause 5.12, upon reasonable request of Sanofi, EXS will grant Sanofi and its Affiliates reasonable access to all results and data (including all primary data and data contained in laboratory notebooks) that is generated in the course of performance of each Research Plan and NSM Research Plan in a format reasonably acceptable to both Parties (including interim results, chemical structures and drug design strategies arising out of the Research Plan or NSM Research Plan). EXS shall consider in good faith any reasonable comments arising out of Sanofi\u2019s review of such results and data and provided by Sanofi in writing to EXS\u2019s Alliance Manager and make reasonable adjustments to the applicable Research Plan or NSM Research Plan in order to account for those reasonable comments. Sanofi and its Affiliates will also have the right, at reasonable intervals and upon reasonable notice to EXS, to have copies of such records made to use and transfer as permitted hereunder. All such records in their disclosed form will be deemed the Confidential Information of each Party (without affecting the ownership of or confidentiality and non-use obligations related to the information therein).\n5.12 Each Party will furnish to the Joint Steering Committee, at each Joint Steering Committee meeting, to the extent applicable to such Party, an update on such Party\u2019s progress under the Research Plan for an Approved Collaboration Target or the NSM Research Plan for any Collaboration NSM Target during the relevant Calendar Quarter, including a summary of any material results and data generated by such Party under such Research Plan or NSM Research Plan since the previous Joint Steering Committee meeting. Such Party shall provide the Joint Steering Committee with such other results, data and other information with respect to the activities under the Research Plan or NSM Research Plan as any member of the Joint Steering Committee may reasonably request that are in such Party\u2019s possession or control and are reasonably necessary or useful for the Joint Steering Committee to perform its responsibilities under Clause 11 or for either Party to exercise its rights under this Agreement. Upon reasonable request by a Party, through the Joint Steering Committee, the other Party shall provide the Joint Steering Committee with such other information and such additional access to records with respect to any Approved Collaboration Target or Collaboration NSM Target that is the subject of a Research Plan or NSM Research Plan as the Joint Steering Committee or such other Party may reasonably request for the conduct or evaluation of the Research Program, including data that is specific to the applicable Research Program (e.g., underlying datasets that are specific to the applicable Research Program and which are used by a Party in the course of conducting its activities with respect to the applicable Research Program). Nothing in this Clause 5.12 will require a Party to provide any data to the other Party if doing so would be contrary to Applicable Laws.\n5.13 Sanofi will have the right to perform [***] activities under a Research Plan for each Approved Collaboration Target, including [***]. In the event of a dispute regarding the scope of the activities to be performed by Sanofi under that Research Plan, Sanofi will have final decision-making authority regarding that scope, and EXS shall not unreasonably withhold, delay or condition its approval of that scope. If Sanofi performs any such activities, then EXS shall transfer, upon Sanofi\u2019s request and at no cost to Sanofi, adequate amounts of materials, which Sanofi may use in accordance with the terms and conditions of this Agreement (including the applicable Research Plan) and any Material Transfer Agreement entered into between the Parties). Prior to EXS transferring any such materials to Sanofi, the Parties shall enter into a Material Transfer Agreement in the form attached as Schedule 5.\n5.14 Sanofi may provide EXS with (a) Sanofi-Originated Molecules Directed To an Approved Collaboration Target or other materials, in each case developed outside of this Agreement and Controlled by Sanofi or its Affiliates (\u201cSanofi Materials\u201d) or (b) Sanofi-Provided Data, which Sanofi may use in accordance with the terms and conditions of this Agreement (including the applicable Research Plan) and any Material Transfer Agreement entered into between the Parties. Prior to Sanofi transferring any Sanofi Materials to EXS, the Parties shall enter into a Material Transfer Agreement in the form attached as Schedule 5.", "size": 5, "hash": "07757ac74251ae52257314c4da07b83a", "id": 2}, {"samples": [{"hash": "gym3iySCjzY", "uri": "/contracts/gym3iySCjzY#research-activities", "label": "Strategic Collaboration, Option and License Agreement", "score": 30.3408622742, "published": true}, {"hash": "550s9kYTeLb", "uri": "/contracts/550s9kYTeLb#research-activities", "label": "Strategic Collaboration, Option and License Agreement (CRISPR Therapeutics AG)", "score": 27.7652301788, "published": true}, {"hash": "jdr0xImj5BW", "uri": "/contracts/jdr0xImj5BW#research-activities", "label": "Strategic Collaboration, Option and License Agreement (CRISPR Therapeutics AG)", "score": 27.516084671, "published": true}], "snippet_links": [{"key": "the-jrc", "type": "clause", "offset": [10, 17]}, {"key": "approval-of", "type": "clause", "offset": [20, 31]}, {"key": "each-party-will", "type": "clause", "offset": [49, 64]}, {"key": "efforts-to-perform", "type": "clause", "offset": [93, 111]}, {"key": "such-party", "type": "clause", "offset": [133, 143]}, {"key": "in-accordance-with", "type": "definition", "offset": [184, 202]}, {"key": "responsible-for", "type": "clause", "offset": [251, 266]}, {"key": "activities-under", "type": "clause", "offset": [291, 307]}, {"key": "crispr-activities", "type": "definition", "offset": [377, 394]}, {"key": "affiliates-and-subcontractors", "type": "clause", "offset": [459, 488]}, {"key": "comply-with", "type": "definition", "offset": [493, 504]}, {"key": "all-applicable-laws", "type": "definition", "offset": [505, 524]}, {"key": "the-activities", "type": "clause", "offset": [553, 567]}, {"key": "where-appropriate", "type": "clause", "offset": [601, 618]}, {"key": "research-plans", "type": "definition", "offset": [680, 694]}, {"key": "target-selection-period", "type": "definition", "offset": [751, 774]}, {"key": "the-final", "type": "clause", "offset": [857, 866]}, {"key": "number-of", "type": "clause", "offset": [918, 927]}, {"key": "the-research", "type": "clause", "offset": [998, 1010]}, {"key": "the-target", "type": "clause", "offset": [1024, 1034]}, {"key": "performance-of-research", "type": "clause", "offset": [1142, 1165]}], "snippet": "Following the JRC\u2019s approval of a Research Plan, each Party will use Commercially Reasonable Efforts to perform activities for which such Party is responsible under such Research Plan in accordance with the timelines set forth therein. Vertex will be responsible for carrying out all Vertex Activities under a Research Plan, and CRISPR will be responsible for carrying out all CRISPR Activities under each Research Plan. Each Party will, and will require its Affiliates and Subcontractors to, comply with all Applicable Laws in its and their conduct of the activities under a Research Plan, including where appropriate cGMP, GCP and GLP (or similar standards). No more than [***] Research Plans shall be conducted at any given time during the Initial Target Selection Period and no more than [***] Research Plans shall be conducted at any given time during the Final Target Selection Period. CRISPR will dedicate such number of FTEs as is reasonably required to perform the CRISPR Activities under the Research Plans during the Target Selection Period, which CRISPR currently anticipates will be no fewer than an average of [***] FTEs to the performance of Research Plans during the Initial Target Selection Period and no fewer than an average of [***] FTEs to the performance of Research Plans during the Final Target Selection Period.", "size": 4, "hash": "261f0d300757f2b60293bcf35f6f91a8", "id": 3}, {"samples": [{"hash": "aF6YpgrfrOu", "uri": "/contracts/aF6YpgrfrOu#research-activities", "label": "Grant Agreement", "score": 22.3284416199, "published": true}, {"hash": "dJJ2rUDqs62", "uri": "/contracts/dJJ2rUDqs62#research-activities", "label": "Grant Agreement", "score": 22.3231639862, "published": true}, {"hash": "eJxMzN0UUX6", "uri": "/contracts/eJxMzN0UUX6#research-activities", "label": "Grant Agreement", "score": 22.0663928986, "published": true}], "snippet_links": [{"key": "research-results", "type": "clause", "offset": [0, 16]}, {"key": "description-of", "type": "clause", "offset": [45, 59]}, {"key": "individual-projects", "type": "clause", "offset": [76, 95]}, {"key": "research-work-plan", "type": "definition", "offset": [137, 155]}, {"key": "joint-publications", "type": "clause", "offset": [303, 321]}, {"key": "directly-related-to", "type": "definition", "offset": [323, 342]}, {"key": "the-work", "type": "definition", "offset": [343, 351]}, {"key": "the-project", "type": "definition", "offset": [370, 381]}, {"key": "acknowledgment-of", "type": "clause", "offset": [445, 462]}, {"key": "the-funding-source", "type": "definition", "offset": [463, 481]}], "snippet": "Research results obtained (including a short description of progress on the individual projects) and deviations, if any, to the original research work plan. \u2022 Scientific highlights and achievements (scientific/technological breakthrough, patents, awards, prizes etc...). \u2022 A full list of individual and joint publications, directly related to the work undertaken within the project (including citation index and impact factor), with appropriate acknowledgment of the funding source. \u2022 Intersectoral and multidisciplinary collaboration.", "size": 4, "hash": "4d359ba670b0a711d4761c939f35e914", "id": 4}, {"samples": [{"hash": "eo4wWf0ZP3", "uri": "/contracts/eo4wWf0ZP3#research-activities", "label": "Collaboration Agreement (Symyx Technologies Inc)", "score": 18.0, "published": true}, {"hash": "biQ8h8u26FR", "uri": "/contracts/biQ8h8u26FR#research-activities", "label": "Collaboration Agreement (Symyx Technologies Inc)", "score": 18.0, "published": true}, {"hash": "9yqtUW8hOm4", "uri": "/contracts/9yqtUW8hOm4#research-activities", "label": "Collaboration Agreement (Symyx Technologies Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "the-terms-and-conditions", "type": "clause", "offset": [11, 35]}, {"key": "the-parties-shall", "type": "clause", "offset": [54, 71]}, {"key": "collaborative-research", "type": "definition", "offset": [80, 102]}, {"key": "in-connection-with", "type": "clause", "offset": [103, 121]}, {"key": "the-research-program", "type": "clause", "offset": [122, 142]}, {"key": "agree-to", "type": "clause", "offset": [225, 233]}, {"key": "identification-of-lead-compounds", "type": "clause", "offset": [251, 283]}], "snippet": "Subject to the terms and conditions set forth herein, the parties shall conduct collaborative research in connection with the Research Program. The parties intend to conduct the Research Program on a collaborative basis, and agree to cooperate in the identification of Lead Compounds.", "size": 3, "hash": "765e588890023ed82ba8a24c1f8af5bc", "id": 5}, {"samples": [{"hash": "hznQTlUwn7b", "uri": "/contracts/hznQTlUwn7b#research-activities", "label": "Collaboration Agreement (Symyx Technologies Inc)", "score": 18.0, "published": true}, {"hash": "fi1bp5MI6JZ", "uri": "/contracts/fi1bp5MI6JZ#research-activities", "label": "Collaboration Agreement (Symyx Technologies Inc)", "score": 18.0, "published": true}, {"hash": "2bz7H6zAnXN", "uri": "/contracts/2bz7H6zAnXN#research-activities", "label": "Collaboration Agreement (Symyx Technologies Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "the-parties-shall", "type": "clause", "offset": [0, 17]}, {"key": "collaborative-research", "type": "definition", "offset": [26, 48]}, {"key": "in-connection-with", "type": "clause", "offset": [49, 67]}, {"key": "the-research-program", "type": "clause", "offset": [68, 88]}], "snippet": "The parties shall conduct collaborative research in connection with the Research Program.", "size": 3, "hash": "c64e03204dd513dc0b6b2a76a456b471", "id": 6}, {"samples": [{"hash": "aBCMkyTmur", "uri": "/contracts/aBCMkyTmur#research-activities", "label": "Research and Development (Ribogene Inc / Ca/)", "score": 18.0, "published": true}, {"hash": "7ybahG2hNwg", "uri": "/contracts/7ybahG2hNwg#research-activities", "label": "Research and Development (Ribogene Inc / Ca/)", "score": 18.0, "published": true}, {"hash": "5aRnF7I3dGx", "uri": "/contracts/5aRnF7I3dGx#research-activities", "label": "Research and Development (Ribogene Inc / Ca/)", "score": 18.0, "published": true}], "snippet_links": [{"key": "all-reasonable-efforts", "type": "definition", "offset": [40, 62]}, {"key": "in-accordance-with", "type": "definition", "offset": [135, 153]}, {"key": "terms-and-conditions-of-this-agreement", "type": "clause", "offset": [158, 196]}, {"key": "plans-and", "type": "clause", "offset": [263, 272]}, {"key": "additional-specifications", "type": "clause", "offset": [277, 302]}, {"key": "in-writing", "type": "clause", "offset": [349, 359]}, {"key": "the-parties-hereto", "type": "clause", "offset": [363, 381]}, {"key": "from-time-to-time", "type": "clause", "offset": [382, 399]}, {"key": "during-the-research-term", "type": "clause", "offset": [400, 424]}, {"key": "per-year", "type": "definition", "offset": [478, 486]}, {"key": "activities-under", "type": "clause", "offset": [509, 525]}, {"key": "in-addition-to", "type": "clause", "offset": [548, 562]}, {"key": "according-to", "type": "definition", "offset": [623, 635]}, {"key": "section-41", "type": "clause", "offset": [654, 665]}, {"key": "abbott-technology", "type": "definition", "offset": [740, 757]}, {"key": "the-program", "type": "clause", "offset": [815, 826]}, {"key": "will-provide", "type": "clause", "offset": [832, 844]}, {"key": "research-data", "type": "definition", "offset": [869, 882]}, {"key": "results-and-conclusions", "type": "clause", "offset": [884, 907]}, {"key": "objectives-of-the-research-program", "type": "clause", "offset": [951, 985]}], "snippet": "2.1 RiboGene Efforts RiboGene shall use all reasonable efforts to expeditiously perform its part of the Research Program substantially in accordance with the terms and conditions of this Agreement, including the descriptions and timetables of the Annual Research Plans and any additional specifications as may be proposed by the JMT and agreed upon in writing by the parties hereto from time to time during the Research Term.\n2.2 Abbott Efforts Abbott shall expend at least [*] per year in support of its own activities under the Research Program, in addition to its separate, but related support of RiboGene's activities, according to the provisions of Section 4.1; shall identify, at its sole option, and permit RiboGene to use pertinent Abbott technology, only during the Research Term, and only for purposes of the Program; and will provide to RiboGene such of its research data, results and conclusions which it deems necessary to accomplish the objectives of the Research Program.", "size": 3, "hash": "956c01c0fb19f57c048ca146c7b3bfc8", "id": 7}, {"samples": [{"hash": "ic3ka3zkxS", "uri": "/contracts/ic3ka3zkxS#research-activities", "label": "Research License and Option Agreement (Abgenix Inc)", "score": 18.0, "published": true}, {"hash": "gkiA24DF0wM", "uri": "/contracts/gkiA24DF0wM#research-activities", "label": "Research License and Option Agreement (Abgenix Inc)", "score": 18.0, "published": true}, {"hash": "8GWUfMvvhuA", "uri": "/contracts/8GWUfMvvhuA#research-activities", "label": "Research License and Option Agreement (Abgenix Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "during-the-term-of-this-agreement", "type": "clause", "offset": [0, 33]}, {"key": "the-parties-will", "type": "clause", "offset": [35, 51]}, {"key": "development-of-products", "type": "clause", "offset": [92, 115]}, {"key": "mutually-agree", "type": "definition", "offset": [128, 142]}, {"key": "in-writing", "type": "clause", "offset": [148, 158]}, {"key": "research-plan", "type": "definition", "offset": [166, 179]}, {"key": "from-time-to-time", "type": "clause", "offset": [208, 225]}, {"key": "requested-by", "type": "clause", "offset": [307, 319]}, {"key": "status-of", "type": "clause", "offset": [341, 350]}, {"key": "the-party", "type": "clause", "offset": [378, 387]}], "snippet": "During the term of this Agreement, the parties will conduct such collaborative research and development of Products as they may mutually agree upon in writing in the Research Plan (as the same may be amended from time to time). During the term of this Agreement, GNE and ABX shall each update the other, as requested by the other, as to the status of any research activities of the party under the Research Plan.", "size": 3, "hash": "db77d1a9fdb3e8d562e90c1061aed082", "id": 8}, {"samples": [{"hash": "6zY23TDFh7A", "uri": "/contracts/6zY23TDFh7A#research-activities", "label": "Research Collaboration and Option Agreement (Morphic Holding, Inc.)", "score": 30.4483222961, "published": true}, {"hash": "cBiWK15Lw3n", "uri": "/contracts/cBiWK15Lw3n#research-activities", "label": "Research Collaboration and Option Agreement (Morphic Holding, Inc.)", "score": 30.4072551727, "published": true}, {"hash": "b285ETTr4rL", "uri": "/contracts/b285ETTr4rL#research-activities", "label": "Research Collaboration and Option Agreement (Morphic Holding, Inc.)", "score": 30.3853530884, "published": true}], "snippet_links": [{"key": "during-the-research-term", "type": "clause", "offset": [0, 24]}, {"key": "research-program", "type": "definition", "offset": [34, 50]}, {"key": "the-jrc", "type": "clause", "offset": [107, 114]}, {"key": "activities-under", "type": "clause", "offset": [163, 179]}, {"key": "status-of", "type": "clause", "offset": [217, 226]}, {"key": "quarterly-basis", "type": "definition", "offset": [323, 338]}, {"key": "written-reports", "type": "definition", "offset": [384, 399]}, {"key": "the-applicable", "type": "clause", "offset": [499, 513]}, {"key": "calendar-quarter", "type": "definition", "offset": [514, 530]}, {"key": "quarterly-reports", "type": "clause", "offset": [537, 554]}, {"key": "with-respect-to", "type": "clause", "offset": [569, 584]}, {"key": "characteristics-of", "type": "definition", "offset": [612, 630]}, {"key": "selection-of-compounds", "type": "clause", "offset": [661, 683]}, {"key": "further-study", "type": "clause", "offset": [688, 701]}, {"key": "late-lead-optimization-activities", "type": "definition", "offset": [763, 796]}, {"key": "following-the", "type": "definition", "offset": [797, 810]}, {"key": "completion-of", "type": "definition", "offset": [811, 824]}, {"key": "in-accordance-with", "type": "definition", "offset": [880, 898]}, {"key": "activities-required", "type": "clause", "offset": [976, 995]}, {"key": "for-\u2587", "type": "clause", "offset": [996, 1001]}, {"key": "maintenance-of", "type": "clause", "offset": [1091, 1105]}, {"key": "joint-patents", "type": "clause", "offset": [1129, 1142]}, {"key": "the-objectives", "type": "clause", "offset": [1300, 1314]}, {"key": "research-plan", "type": "definition", "offset": [1365, 1378]}, {"key": "in-addition", "type": "clause", "offset": [1380, 1391]}, {"key": "promptly-report", "type": "definition", "offset": [1406, 1421]}, {"key": "other-results", "type": "clause", "offset": [1426, 1439]}, {"key": "reasonably-likely", "type": "definition", "offset": [1471, 1488]}, {"key": "at-any-time", "type": "clause", "offset": [1519, 1530]}, {"key": "during-the-option-period", "type": "clause", "offset": [1531, 1555]}, {"key": "respond-to", "type": "clause", "offset": [1602, 1612]}, {"key": "of-activities", "type": "clause", "offset": [1674, 1687]}], "snippet": "During the Research Term for each Research Program, Morphic will keep \u2587\u2587\u2587\u2587\u2587\u2587\u2587 reasonably informed, through the JRC, regarding the status and progress of Morphic\u2019s activities under such Research Program, including the status of all Morphic Research Activities. During the Research Term for a Research Program, on a Calendar Quarterly basis, Morphic will prepare and provide to the JRC written reports on the status of all such Morphic Research Activities performed under such Research Program during the applicable Calendar Quarter. Such quarterly reports will include, with respect to such Research Program, the characteristics of any Compounds identified, the selection of Compounds for further study (including those for which \u2587\u2587\u2587\u2587\u2587\u2587\u2587 may determine to commence Late Lead Optimization Activities following the completion of Lead Optimization Activities for such Research Program in accordance with Section 2.5 (Late Lead Optimization Activities)), completed Morphic Research Activities required for \u2587\u2587\u2587\u2587\u2587\u2587\u2587 to commence IND-Enabling Studies for such Research Program and the Prosecution and Maintenance of any Morphic Patents or Joint Patents Covering any such Compounds. Such reports must be sufficient in content to allow \u2587\u2587\u2587\u2587\u2587\u2587\u2587 to evaluate the progress of the Morphic Research Activities against the objectives and timelines included therefor in the applicable Research Plan. In addition, Morphic will promptly report any other Results of a Research Program that are reasonably likely to be significant to the JRC. At any time during the Option Period for a Research Program, Morphic will promptly respond to any reasonable inquiries from \u2587\u2587\u2587\u2587\u2587\u2587\u2587 regarding the progress of activities under such Research Program (including any Morphic Research Activities).", "size": 3, "hash": "d56f6b2cfdc8b19ec55a90984dcbb32f", "id": 9}, {"samples": [{"hash": "6zY23TDFh7A", "uri": "/contracts/6zY23TDFh7A#research-activities", "label": "Research Collaboration and Option Agreement (Morphic Holding, Inc.)", "score": 30.4483222961, "published": true}, {"hash": "cBiWK15Lw3n", "uri": "/contracts/cBiWK15Lw3n#research-activities", "label": "Research Collaboration and Option Agreement (Morphic Holding, Inc.)", "score": 30.4072551727, "published": true}, {"hash": "b285ETTr4rL", "uri": "/contracts/b285ETTr4rL#research-activities", "label": "Research Collaboration and Option Agreement (Morphic Holding, Inc.)", "score": 30.3853530884, "published": true}], "snippet_links": [{"key": "transfer-to", "type": "definition", "offset": [13, 24]}, {"key": "copies-of", "type": "definition", "offset": [33, 42]}, {"key": "the-performance", "type": "clause", "offset": [104, 119]}, {"key": "after-the-effective-date", "type": "clause", "offset": [179, 203]}, {"key": "selection-of", "type": "clause", "offset": [242, 254]}, {"key": "replacement-target", "type": "clause", "offset": [259, 277]}, {"key": "in-accordance-with", "type": "definition", "offset": [293, 311]}, {"key": "calendar-quarter", "type": "definition", "offset": [356, 372]}, {"key": "research-term", "type": "clause", "offset": [401, 414]}, {"key": "research-program", "type": "definition", "offset": [421, 437]}, {"key": "related-to", "type": "clause", "offset": [511, 521]}, {"key": "the-\u2587", "type": "clause", "offset": [522, 527]}, {"key": "activities-under", "type": "clause", "offset": [543, 559]}, {"key": "transfer-of", "type": "clause", "offset": [664, 675]}, {"key": "notwithstanding-anything-to-the-contrary", "type": "clause", "offset": [765, 805]}, {"key": "in-this-agreement", "type": "definition", "offset": [816, 833]}, {"key": "cmcc-license-agreement", "type": "definition", "offset": [979, 1001]}], "snippet": "Morphic will transfer to \u2587\u2587\u2587\u2587\u2587\u2587\u2587 copies of any and all Morphic Know-How that is necessary or useful for the performance of all \u2587\u2587\u2587\u2587\u2587\u2587\u2587 Research Activities (a) no later than [***] after the Effective Date and (b) no later than [***] after the selection of any Replacement Target MoA by \u2587\u2587\u2587\u2587\u2587\u2587\u2587 in accordance with Section 2.6.1 (Replacement Decisions). Each Calendar Quarter during the remainder of the Research Term for a Research Program, Morphic will transfer to \u2587\u2587\u2587\u2587\u2587\u2587\u2587 copies of any Morphic Know-How that is related to the \u2587\u2587\u2587\u2587\u2587\u2587\u2587 Research Activities under such Research Program and that is made, conceived, discovered or otherwise generated since the previous transfer of such Know-How to continue to enable \u2587\u2587\u2587\u2587\u2587\u2587\u2587 to perform such \u2587\u2587\u2587\u2587\u2587\u2587\u2587 Research Activities. Notwithstanding anything to the contrary set forth in this Agreement, Morphic will not, and will cause its Affiliates not to, disclose to \u2587\u2587\u2587\u2587\u2587\u2587\u2587 or any of its Affiliates any Know-How licensed to Morphic under the CMCC License Agreement.", "size": 3, "hash": "717e58b161b189f75ef8b669f2e33306", "id": 10}], "next_curs": "ClwSVmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjgLEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2IhxyZXNlYXJjaC1hY3Rpdml0aWVzIzAwMDAwMDBhDKIBAmVuGAAgAA==", "clause": {"title": "Research Activities", "parents": [["research", "Research"], ["research-program", "Research Program"], ["scope-of-collaboration-collaboration-activities", "Scope of Collaboration Collaboration Activities"], ["research-collaboration", "Research Collaboration"], ["liability", "Liability"]], "children": [["research-plan", "Research Plan"], ["research-funding", "Research Funding"], ["general", "GENERAL"], ["symyx-responsibilities", "Symyx Responsibilities"], ["identification-of-applicable-assays-and-success-criteria", "IDENTIFICATION OF APPLICABLE ASSAYS AND SUCCESS CRITERIA"]], "size": 151, "id": "research-activities", "related": [["collaboration-activities", "Collaboration activities", "Collaboration activities"], ["development-activities", "Development Activities", "Development Activities"], ["research-program", "Research Program", "Research Program"], ["development-program", "Development Program", "Development Program"], ["development-and-commercialization", "Development and Commercialization", "Development and Commercialization"]], "related_snippets": [], "updated": "2026-03-11T06:07:41+00:00"}, "json": true, "cursor": ""}}